| GERN Shares Outstanding History Table | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Below is a table of the GERN shares outstanding history going back to 2/23/2010:
Also see: GERN Market Cap History GERN YTD Return |
GERN Shares Outstanding History — Geron Share Count Over Time
As of 7/31/2026 Geron has 642.47 million GERN shares outstanding. Investors often track the GERN shares outstanding history to compare shareholder return trends against the change in share count over time.
This page shows GERN share count trends over time, with 66 historical shares outstanding datapoints presented, dating back to 2/23/2010.
| GERN Shares Outstanding History Chart | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
GERN Historical Shares Outstanding: +11.77% CAGR 
Mouse over chart for data details
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| GERN Stock Price Chart |
| About Geron Corp. |
| Geron Corporation is a late-stage clinical biopharmaceutical company developing investigational first-in-class telomerase inhibitor, imetelstat, to treat hematologic malignancies. Co. is engaged in the development of therapeutic products for oncology. Its lead indication for imetelstat is in Low or Intermediate-1 risk myelodysplastic syndromes. It is developing imetelstat for the treatment of several myeloid hematologic malignancies, including a Phase 3 clinical trial, named IMpactMF, in relapsed/refractory myelofibrosis (MF) with overall survival as the primary endpoint, that is enrolling patients. We show 66 historical shares outstanding datapoints in our coverage of GERN's shares outstanding history. Understanding the changing numbers of GERN shares outstanding — and comprehending the concept of differing number of shares outstanding in general comparing companies like GERN versus peers — is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies. Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history. With this page we aim to empower investors researching GERN by allowing them to research GERN shares outstanding history as well as any other stock in our coverage universe. |
| GERN Current Stock Quote |
Quotes delayed 20 minutes  Free GERN Email Alerts:
Get Dividend Alerts 
Get SEC Filing Alerts
|
| Video: Shares Outstanding Importance | |
|
Video: Shares Outstanding Importance
| GERN Share Performance |
| Shares Outstanding Peers |
| Geron (GERN) is categorized under the Healthcare sector; to help you further research historical shares outstanding numbers, below are some other companies in the same sector:
GFOR Shares Outstanding History GH Shares Outstanding History GHDX Shares Outstanding History GILD Shares Outstanding History GKOS Shares Outstanding History GLSI Shares Outstanding History GLTO Shares Outstanding History GLUE Shares Outstanding History GLXY Shares Outstanding History GLYC Shares Outstanding History More Healthcare companies » |
GERN Shares Outstanding History | www.SharesOutstandingHistory.com | Copyright © 2017 - 2026, All Rights Reserved
Nothing in SharesOutstandingHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel
from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners.
None of the information contained herein constitutes a recommendation that any particular security, portfolio,
transaction, or investment strategy is suitable for any specific person. All viewers agree that under no
circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held
liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you
agree to the following Full Disclaimer & Terms of Use and
Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at
least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.
